PMID- 16739308
OWN - NLM
STAT- MEDLINE
DCOM- 20060612
LR  - 20131121
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 26
IP  - 1B
DP  - 2006 Jan-Feb
TI  - Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving 
      platinum and non-platinum chemotherapy: a meta-analysis.
PG  - 479-84
AB  - BACKGROUND: Anaemia is a common complication of chemotherapy (CT), including both 
      non-platinum (Pt)-based as well as Pt-based CT. PATIENTS AND METHODS: Patients 
      from three controlled trials with solid tumours receiving either Pt- or 
      non-Pt-based CT, who had been randomised to epoetin beta treatment or standard 
      care, were included in this meta-analysis (n=255, n=199, respectively), to see if 
      epoetin beta was equally effective in both CT types. The primary endpoint was 
      haemoglobin (Hb) change. Secondary end-points included transfusion requirement, 
      adverse events (AEs), survival, time to tumour progression and thromboembolic 
      events (TEEs). RESULTS: All patients responded rapidly to epoetin beta treatment, 
      showing a median Hb increase of > or = 1 g/dl from baseline at week 4. A median 
      Hb of 12.2, 12.5 and 11.8 g/dl was achieved in all patients, those receiving 
      Pt-based CT and those receiving non-Pt-based CT, respectively, after 16 weeks of 
      treatment. Transfusion risk reductions associated with epoetin beta treatment of 
      53% (p<0.0001), 61% (p<0.0001) and 26% (non significant) were observed for all 
      patients, Pt- and non-Pt-based CT patients, respectively. Overall, for all three 
      populations, there were no risks identified for tumour progression or overall 
      survival. There was a statistically non-significant incidence of TEEs (5.9% 
      versus 4.5%) and no marked differences were observed between groups for frequency 
      or type of AEs reported. CONCLUSION: The type of CT has no impact on the ability 
      of epoetin beta to rapidly increase Hb in patients with solid tumours and 
      CT-induced anaemia.
FAU - Boogaerts, M
AU  - Boogaerts M
AD  - University Hospital Gasthuisberg, Leuven, Belgium. marc.boogaerts@uz.kuleuven.be
FAU - Oberhoff, C
AU  - Oberhoff C
FAU - Ten Bokkel Huinink, W
AU  - Ten Bokkel Huinink W
FAU - Nowrousian, M R
AU  - Nowrousian MR
FAU - Hayward, C R W
AU  - Hayward CR
FAU - Burger, H U
AU  - Burger HU
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Hemoglobins)
RN  - 0 (Recombinant Proteins)
RN  - 0 (epoetin beta)
RN  - 11096-26-7 (Erythropoietin)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia/blood/chemically induced/*drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Cisplatin/administration & dosage/adverse effects
MH  - Erythropoietin/*administration & dosage
MH  - Female
MH  - Hemoglobins/metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/blood/*complications/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Recombinant Proteins
EDAT- 2006/06/03 09:00
MHDA- 2006/06/13 09:00
CRDT- 2006/06/03 09:00
PHST- 2006/06/03 09:00 [pubmed]
PHST- 2006/06/13 09:00 [medline]
PHST- 2006/06/03 09:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2006 Jan-Feb;26(1B):479-84.